Investment Rating - The industry investment rating is "Buy" for companies with strong functional attributes and emotional consumption characteristics, particularly those with good digital infrastructure [4][9]. Core Insights - The report emphasizes that digital capabilities will become a core competitive advantage for consumer goods companies in the future [3]. - The domestic market is expected to continue experiencing consumption differentiation, with intense competition among existing players. Local brands with strong functional and emotional attributes are likely to perform better [4][9]. - The report highlights the importance of digitalization and artificial intelligence as strategic focuses for overseas consumer brands, which are increasingly investing in product innovation and operational efficiency [9]. Summary by Sections Industry Overview - The textile and apparel industry is undergoing transformation, with a focus on brands that possess genuine brand power [8]. - Traditional luxury brands are facing sales pressure in the Chinese market, with many reporting declines in sales [9]. Investment Recommendations - The report suggests focusing on companies in the outdoor sports, beauty, and jewelry sectors that exhibit strong functional attributes and emotional consumption characteristics, such as Anta Sports, Bosideng, and Proya [4][9]. - The report notes that brands with strong efficacy and emotional value continue to see good growth in the Chinese market, contrasting with the struggles of traditional luxury brands [9]. Market Dynamics - The report indicates that the Asia-Pacific market, particularly China, accounts for a significant portion of overseas brands' revenue, making localization strategies essential for these brands [9]. - The report also mentions that the application of digitalization and AI is becoming increasingly important for enhancing product innovation and consumer engagement [9].

| 代码 | 名称 | 最新价 | 涨跌幅 ▽ | | --- | --- | --- | --- | | 02145 | 下美股份 | 81.500 | 7.73% | | 06181 | 老铺黄金 | 731.500 | 6.01% | | 09863 | 零跑汽车 | 61.250 | 4.88% | | 02367 | 巨子生物 | 57.200 | 2.97% | | 01364 | 古茗 | 23.620 | 2.92% | | 09992 | 泡泡玛特 | 250.000 | 2.80% | | 01810 | 小米集团-W | 54.500 | 2.06% | | 09985 | 卫龙美味 | 12.160 | 1.50% | | 09868 | 小鹏汽车-W | 72.350 | 1.47% | | 01405 | 达势股份 | 85.250 | 1.31% | | 01318 | 毛戈平 | 100.400 | 0.80% | | 09896 | 名创优品 | 37.180 | 0.35% | | 09866 | 蔚来-SW | 37.920 | 0.32% | | 02097 | 蜜雪集 ...

Core Insights - The Invesco Great Wall Hong Kong Stock Connect Global Competitiveness C Fund (012228) has a latest net value of 0.8108 yuan, with a weekly return of -3.14%, a three-month return of 6.14%, and a year-to-date return of 17.87% [1] - The fund was established on August 12, 2021, and managed by Zhou Hanying, with a total scale of 250 million yuan as of June 30, 2025 [1] - The top ten stock holdings of the fund include Tencent Holdings, Alibaba-W, Pop Mart, Xiaomi Group-W, Giant Bio, Zijin Mining, NetEase Cloud Music, China Pacific Insurance, SMIC, and SF Holding, accounting for a total of 47.14% of the portfolio [1]

Investment Rating - The report maintains a "Positive" investment rating, highlighting the favorable momentum in new consumption sectors, particularly in beauty care, gold, trendy toys, and freshly brewed tea drinks [4]. Core Insights - The new consumption landscape reflects the evolving consumer preferences of the younger generation, emphasizing the importance of understanding these narratives for capturing growth opportunities in new consumption companies [80]. Beauty Care Sector - The high-end beauty segment is expected to grow faster than the mass market, with projected CAGR for high-end skincare and makeup at 9.6% and 10.8% respectively from 2023 to 2028, compared to 8.2% and 6.7% for mass-market products [5][9]. - Domestic brands are gaining market share, with the national beauty market share reaching 50.4% in 2023, surpassing foreign brands [15][18]. Gold Jewelry Sector - The gold jewelry market in China is projected to grow from 820 billion yuan in 2023 to 1,140 billion yuan by 2028, with a CAGR of 6.8% [19]. - The ancient gold segment shows strong growth potential, with a CAGR of 21.8% expected from 2023 to 2028, despite a slowdown in growth rates [24][25]. Trendy Toys Sector - The trendy toy market in China reached 626 billion yuan in 2023, with a CAGR of 31.24% from 2019 to 2023, indicating rapid growth [40]. - The market concentration is increasing, with the top five companies' market share rising from 22.8% in 2019 to 26.4% in 2021 [46]. Freshly Brewed Tea Drinks Sector - The freshly brewed tea drink market in China was valued at 517.5 billion yuan in 2023, accounting for 36.3% of the beverage market, with expectations to reach 1,163.4 billion yuan by 2028 [67]. - The market for freshly brewed tea drinks is anticipated to maintain its position as the largest segment within the freshly brewed beverage category, with a projected CAGR of 17.3% from 2023 to 2028 [71][75].

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown positive performance, with significant increases in constituent stocks, indicating a favorable market environment for healthcare investments [3][4]. Group 1: Market Performance - As of July 28, 2025, the HSHCI rose by 0.64%, with notable gains from stocks such as MicroPort Medical (up 9.51%) and Eddy Health Holdings (up 3.93%) [3]. - The Hang Seng Healthcare ETF (513060) opened higher, increasing by 1.22% to a latest price of 0.66 yuan, and has accumulated a 0.92% rise over the past week [3]. - The ETF recorded a turnover of 0.79% during the trading session, with a transaction volume of 61.18 million yuan, and an average daily trading volume of 2.815 billion yuan over the past week, ranking first among comparable funds [3]. Group 2: Policy and Industry Outlook - The national procurement policy is expected to expand from pharmaceuticals to medical devices, potentially leading to performance reversals in high-value consumables and in vitro diagnostics sectors [4]. - The medical device sector is anticipated to benefit from a recovery in procurement activities this year, with expectations of an earnings turning point in the third quarter [4]. Group 3: ETF Performance Metrics - The latest size of the Hang Seng Healthcare ETF is 7.656 billion yuan, placing it in the top third among comparable funds [4]. - The ETF has seen a net value increase of 29.88% over the past two years, with a maximum monthly return of 28.34% since inception [4]. - The ETF's Sharpe ratio for the past year is 2.30, indicating strong risk-adjusted returns [4]. Group 4: Valuation and Tracking Accuracy - The HSHCI's latest price-to-earnings ratio (PE-TTM) is 31.72, which is below 84.29% of the historical data over the past three years, suggesting a low valuation [6]. - The ETF has the highest tracking accuracy among comparable funds, with a tracking error of 0.060% over the past year [6]. - The top ten weighted stocks in the HSHCI account for 60.54% of the index, including companies like BeiGene and WuXi Biologics [6].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights a moderate recovery in the beauty and cosmetics sector, with a notable performance in hair care and color cosmetics, indicating a stable growth trajectory [7][35] - The medical aesthetics sector is expected to gain momentum from the introduction of innovative products, particularly in the field of collagen and hair loss treatments [30][46] Summary by Sections Market Review - In June, the beauty and personal care index fell by 3.61%, ranking 31st among all primary industries, underperforming the market [14] - The medical aesthetics sector saw significant stock price increases for companies like Meili Tianyuan Medical Health (+64.4%), Yonghe Medical (+50.0%), and Sihuan Pharmaceutical (+13.3%) [20][26] - For the first half of 2025, the medical aesthetics sector recorded substantial gains, with Jinbo Biological (+124.6%), Yonghe Medical (+83.3%), and Meili Tianyuan Medical Health (+69.9%) leading the way [20][26] Medical Aesthetics - Jinbo Biological launched the world's first recombinant type III humanized collagen gel, HiveCOL, which is expected to revolutionize tissue regeneration [30] - Sihuan Pharmaceutical introduced new products targeting skin quality improvement and contour shaping, while Kedi's external finasteride spray received approval, marking a significant advancement in hair loss treatment [31][32] Cosmetics - The retail sales of cosmetics in the first half of 2025 reached 229.1 billion yuan, reflecting a year-on-year growth of 2.9% [35] - Online sales of cosmetics amounted to 267.83 billion yuan, growing by 11.1%, while offline sales decreased by 4.1% to 228.44 billion yuan [36] - The report emphasizes the strong performance of domestic brands in the online market, particularly on platforms like Douyin and Tmall [40][43] Investment Recommendations - The report recommends focusing on leading domestic beauty brands that are expected to gain market share, particularly in high-growth segments [46][47] - Key recommendations include companies like Shangmei Co., Ltd., Maogeping, and Pulaia, which are well-positioned to benefit from the ongoing trends in the beauty market [50]

Core Viewpoint - The hair care market is experiencing significant growth, with online transaction value reaching 340.37 billion yuan in the first half of 2025, marking a year-on-year increase of 20.67% [4][5]. Market Performance - The hair care segment outperformed other beauty categories, driven by a 131.5% surge in men's hair care and steady performances from international brands like Kérastase, L'Oréal, and Pantene [2][4]. - The overall beauty market saw a total online transaction value of 3,060.39 billion yuan, with hair care being one of the fastest-growing segments [5]. Segment Breakdown - The hair care subcategories showed robust growth: - Hair cleansing: 179.72 billion yuan, up 21.56% - Hair care: 74.00 billion yuan, up 19.59% - Hair dyeing and perming: 57.44 billion yuan, up 17.20% - Hair styling: 20.76 billion yuan, up 16.64% - Men's hair care: 5.12 billion yuan, up 131.50% [7]. Brand Landscape - The market share of the top five brands (CR5) decreased from 19% in 2024 to 16%, indicating increased competition from emerging domestic brands and private labels [8]. - New domestic brands like Off&Relax and others are gaining traction, with several entering the top 20 rankings [11]. Consumer Trends - There is a shift towards efficacy-driven products, with consumers seeking solutions for specific scalp issues and multi-functional products [14][19]. - The introduction of "face-care level" ingredients in hair care products is becoming a trend, enhancing the overall consumer experience [19][21]. Innovation and New Products - Over 25 brands launched new products in the first half of 2025, with a focus on scalp care and multi-functional benefits [13]. - Brands are emphasizing rapid effectiveness, with products claiming visible results in as little as one to three minutes [17]. Future Outlook - The competition in the hair care market is expected to intensify, particularly in the areas of anti-hair loss and scalp care, with a focus on patented technologies and quick results [26][29]. - The potential for growth in differentiated segments like scalp oils is significant, as brands explore new opportunities [23][26].

Group 1 - The new consumption concept stocks in the Hong Kong market experienced a decline, with notable drops in specific companies [1] - Old Poo Gold (06181.HK) fell over 6%, indicating significant market reaction [1] - Other companies such as Gu Ming (01364.HK), Bluco (00325.HK), and Juzi Bio (02367.HK) also saw declines exceeding 4% [1]

Group 1 - The core point of the article highlights the performance and management details of the Green Fund's Green Hong Kong Stock Connect Selected Mixed C Fund, which experienced a significant decrease in net assets by 55.76% to 0.07 billion yuan as of June 30, 2025 [1] - The fund manager, Liu Zan, has a strong background in finance, holding a master's degree in science from the State University of New York and has held various positions in asset management since 2009 [1] - The fund has shown impressive returns, with a 3-month yield of 21.12%, a 1-year yield of 62.68%, and an overall yield of 55.51% since inception [2] Group 2 - Recent changes in fund size indicate no subscriptions but some redemptions, leading to a total fund size of 0.02 billion units and a net asset value of 0.02 billion yuan as of June 30, 2025, reflecting a net asset change rate of -24.80% [2] - The top ten stock holdings of the fund account for a significant portion of the portfolio, with a combined weight of 87.11%, including companies like Shenzhou International and China Gas [2] - Green Fund Management Co., Ltd. was established in November 2016 in Beijing, focusing on capital market services with a registered capital of 200 million yuan [2]

Group 1 - The core viewpoint of the article highlights the competitive landscape of the Chinese medical beauty injection materials industry, focusing on regional distribution, market competition, and domestic substitution [1][2][5][6][8]. Group 2 - In terms of regional competition, Shandong Province has the highest number of enterprises in the medical beauty injection materials industry, including raw material producers like Huaxi Biological and equipment manufacturers like Weigao [1]. - The main competitors in the medical beauty injection materials market include Huaxi Biological, Aimeike, and Haohai Biological for hyaluronic acid products, while Jinbo Biological and Juzhi Biological lead in collagen products [2]. - The market structure for medical beauty injection materials in 2024 shows that hyaluronic acid accounts for approximately 36% and botulinum toxin for about 29% of the market [5]. Group 3 - As of May 2025, the number of domestic approvals for hyaluronic acid is comparable to imports, while domestic approvals for regenerative materials exceed imports; however, domestic approvals for botulinum toxin and collagen are lower than imports [6]. - The competition in the industry is intense, with hyaluronic acid and botulinum toxin dominating the market; foreign companies hold an advantage in the high-end market, while domestic companies like Huaxi Biological and Aimeike lead in the mid-to-low-end market through cost-effectiveness and technological innovation [8]. - The threat of substitutes is significant, with non-surgical options like phototherapy and topical skincare products capturing part of the market demand [8].